DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced consolidated results for the third quarter of 2007 and for the nine-month period ended September 30, 2007. For the third quarter of 2007, Neoprobe reported a net loss of $942,000 or $0.01 per share compared to a net loss of $1.7 million or $0.03 per share for the third quarter in 2006. For the nine months ended September 30, 2007, Neoprobe reported a net loss of $3.2 million or $0.05 per share compared to a net loss of $3.4 million or $0.06 per share for the same period in 2006. The net loss for the third quarter of 2007 included $755,000 in non-cash charges compared to total non-cash charges of $362,000 for the third quarter of 2006. The net loss for the nine-month period ended September 30, 2007 included $1.5 million in non-cash charges compared to total non-cash charges of $1.1 million for the same period in 2006. Non-cash charges for both periods consisted primarily of the amortization of warrant and debt-issuance costs in addition to depreciation and amortization of fixed and intangible assets.
